
    
      eligibility criteria: Men and women old of 18 to 65 years with chronic hepatitis B HBeAg
      positive treated with nucleoside and/or nucleotide analogues for 1-2 years and with partial
      response (HBeAg loss and HBV DNA <1000copies/ml).
    
  